Table 2. Clinical features of patients and controls.

	Cancer set				Control set
	n =20	Average	BARHL2 gene methylation (%)	P -value	n =10	Average	BARHL2 gene methylation (%)	P -value
Age		72.3±7.0	36.4±14.0	0.28		62.7±13.3	7.8±2.7	0.83
Male	12	71.1±8.2	38.8±13.2		7	64.0±13.1	7.6±3.0
Female	8	74.0±4.8	32.8±15.2		3	62.0±16.1	9.2±1.8
Histology (adenocarcinoma)				0.9
Well differentiated	7		34.6±16.0
Moderately differentiated	6		37.2±17.8
Poorly differentiated	7		37.6±9.6
Stage				0.71
I	10		35.5±14.2
II/III/IV	10		37.3±14.5
Lymphnode metastasis				0.4
Positive	8		38.6±15.9
Negative	12		34.9±13.1
Helicobacter pylori infection				0.68				0.91
Positive	14		36.1±13.0		5		7.7±3.3
Negative	6		37.0±17.4		5		8.5±2.3
Atrophy				NA				0.91
Non-atrophy	0		NA		5		8.5±2.3
Closed type	5		33.4±16.8	0.76	2		7.3±2.1	0.8
Open type	15		37.4±13.4		3		8.0±4.4

BARHL2, BarH-like 2 homeobox protein; NA, not applicable.

Cancer n=20 and non-cancer n=10.